Source: China – South China Morning PostA potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements by Chinese biotechnology firms to license development rights for innovative medicines to global pharmaceutical firms, according to lawyers advising the companies.
Many of these deals use a so-called newco structure, which combines traditional intellectual property licensing with fundraising via a newly established corporate vehicle, said the Shanghai-based partners…Read More